Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 8;9(11):330.
doi: 10.3390/v9110330.

Characterization of Nucleoside Reverse Transcriptase Inhibitor-Associated Mutations in the RNase H Region of HIV-1 Subtype C Infected Individuals

Affiliations

Characterization of Nucleoside Reverse Transcriptase Inhibitor-Associated Mutations in the RNase H Region of HIV-1 Subtype C Infected Individuals

Sinaye Ngcapu et al. Viruses. .

Abstract

The South African national treatment programme includes nucleoside reverse transcriptase inhibitors (NRTIs) in both first and second line highly active antiretroviral therapy regimens. Mutations in the RNase H domain have been associated with resistance to NRTIs but primarily in HIV-1 subtype B studies. Here, we investigated the prevalence and association of RNase H mutations with NRTI resistance in sequences from HIV-1 subtype C infected individuals. RNase H sequences from 112 NRTI treated but virologically failing individuals and 28 antiretroviral therapy (ART)-naive individuals were generated and analysed. In addition, sequences from 359 subtype C ART-naive sequences were downloaded from Los Alamos database to give a total of 387 sequences from ART-naive individuals for the analysis. Fisher's exact test was used to identify mutations and Bayesian network learning was applied to identify novel NRTI resistance mutation pathways in RNase H domain. The mutations A435L, S468A, T470S, L484I, A508S, Q509L, L517I, Q524E and E529D were more prevalent in sequences from treatment-experienced compared to antiretroviral treatment naive individuals, however, only the E529D mutation remained significant after correction for multiple comparison. Our findings suggest a potential interaction between E529D and NRTI-treatment; however, site-directed mutagenesis is needed to understand the impact of this RNase H mutation.

Keywords: HIV-1; NRTIs; RNase H; mutations; resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Natural variability in 387 RNAse H subtype C sequences and in 1782 RNAse H subtype B sequences from ART-naive patients. The consensus amino acid at each position is coloured according to frequency.
Figure 2
Figure 2
The frequency (%) of treatment-associated mutations in antiretroviral therapy (ART)-naive patients and ART-experienced patients.
Figure 3
Figure 3
Annotated Bayesian network, based on 500 bootstraps, showing graphically the learned associations between nodes denoting amino acids or treatment experience. An arc (arrows) represents a direct dependency between corresponding nodes and arc thickness is proportional to bootstrap support. An antagonistic arc with a wild type was treated the same as a synergistic arc with mutations at this position. Arc direction has no causal meaning, but may indicate a non-additive multivariate effect.

Similar articles

Cited by

References

    1. UNAIDS Global AIDS Update. [(accessed on 7 June 2017)];2016 Available online: http://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016.
    1. Department of Health National Comprehensive HIV and AIDS plan statistics; South Africa. [(accessed on 7 June 2017)];2008 Available online: http://www.health.gov.za/edp.php.
    1. Meintjes G., Moorhouse M.A., Carmona S., Davies N., Dlamini S., van Vuuren C., Manzini T., Mathe M., Moosa Y., Nash J., et al. Adult antiretroviral therapy guidelines 2017. S. Afr. J. HIV Med. 2017;18:1–24. doi: 10.4102/sajhivmed.v18i1.776. - DOI - PMC - PubMed
    1. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS. 2006;20:W13–W23. doi: 10.1097/01.aids.0000247564.73009.bc. - DOI - PubMed
    1. Taylor B.S., Sobieszczyk M.E., McCutchan F.E., Hammer S.M. The challenge of HIV-1 subtype diversity. N. Engl. J. Med. 2008;358:1590–1602. doi: 10.1056/NEJMra0706737. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources